Abstract

With the rapid advancement of sequencing technologies, next generation sequencing (NGS) analysis has been widely applied in cancer genomics research. More recently, NGS has been adopted in clinical oncology to advance personalized medicine. Clinical applications of precision oncology require accurate tests that can distinguish tumor-specific mutations from artifacts introduced during NGS processes or data analysis. Therefore, there is an urgent need to develop best practices in cancer mutation detection using NGS and the need for standard reference data sets for systematically measuring accuracy and reproducibility across platforms and methods. Within the SEQC2 consortium context, we established paired tumor-normal reference samples and generated whole-genome (WGS) and whole-exome sequencing (WES) data using sixteen library protocols, seven sequencing platforms at six different centers. We systematically interrogated somatic mutations in the reference samples to identify factors affecting detection reproducibility and accuracy in cancer genomes. These large cross-platform/site WGS and WES datasets using well-characterized reference samples will represent a powerful resource for benchmarking NGS technologies, bioinformatics pipelines, and for the cancer genomics studies.

Measurement(s)

Somatic Mutation Analysis

Technology Type(s)

whole genome sequencing • Whole Exome Sequencing

Factor Type(s)

sequencing platform • sample prepration • library preparation • bioinformatics method

Sample Characteristic - Organism

Homo sapiens

Machine-accessible metadata file describing the reported data: https://doi.org/10.6084/m9.figshare.16713655

Details

Title
Whole genome and exome sequencing reference datasets from a multi-center and cross-platform benchmark study
Author
Zhao, Yongmei 1   VIAFID ORCID Logo  ; Fang Li Tai 2   VIAFID ORCID Logo  ; Tsai-wei, Shen 1   VIAFID ORCID Logo  ; Choudhari Sulbha 1 ; Talsania Keyur 1 ; Chen Xiongfong 1 ; Shetty Jyoti 3 ; Kriga Yuliya 3 ; Tran, Bao 3 ; Zhu, Bin 4   VIAFID ORCID Logo  ; Chen, Zhong 5 ; Chen Wanqiu 5   VIAFID ORCID Logo  ; Wang, Charles 5   VIAFID ORCID Logo  ; Jaeger Erich 6 ; Daoud, Meerzaman 7 ; Lu, Charles 8 ; Idler, Kenneth 8 ; Ren Luyao 9 ; Zheng Yuanting 9 ; Shi Leming 9 ; Petitjean Virginie 10 ; Sultan, Marc 10 ; Hung, Tiffany 11 ; Peters, Eric 11 ; Drabek Jiri 12 ; Vojta Petr 12 ; Maestro, Roberta 13 ; Gasparotto Daniela 14 ; Sulev, Kõks 15   VIAFID ORCID Logo  ; Reimann Ene 16   VIAFID ORCID Logo  ; Scherer, Andreas 17 ; Nordlund, Jessica 18 ; Liljedahl Ulrika 19 ; Foox Jonathan 20 ; Mason, Christopher E 20   VIAFID ORCID Logo  ; Xiao Chunlin 21   VIAFID ORCID Logo  ; Hong Huixiao 22   VIAFID ORCID Logo  ; Xiao Wenming 23   VIAFID ORCID Logo 

 Frederick National Laboratory for Cancer Research, Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394) 
 Bioinformatics Research & Early Development, Roche Sequencing Solutions Inc., Belmont, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718) 
 Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394) 
 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) 
 Loma Linda University, Center for Genomics, School of Medicine, Loma Linda, USA (GRID:grid.43582.38) (ISNI:0000 0000 9852 649X) 
 Core Applications Group, Product Development, Illumina Inc, Foster City, USA (GRID:grid.185669.5) (ISNI:0000 0004 0507 3954) 
 National Cancer Institute, National Institutes of Health, Computational Genomics and Bioinformatics Branch, Center for Biomedical Informatics and Information Technology, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) 
 AbbVie Genomics Research Center, North Chicago, USA (GRID:grid.48336.3a) 
 Fudan University, State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443) 
10  Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979) 
11  Companion Diagnostics Development, Oncology Biomarker Development, Genentech, South San Francisco, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718) 
12  Palacky University, IMTM, Faculty of Medicine and Dentistry, Olomouc, Czech Republic (GRID:grid.10979.36) (ISNI:0000 0001 1245 3953); Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.10979.36) 
13  Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.10979.36); Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy (GRID:grid.418321.d) (ISNI:0000 0004 1757 9741) 
14  Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.418321.d); Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy (GRID:grid.418321.d) (ISNI:0000 0004 1757 9741) 
15  Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.418321.d); Perron Institute for Neurological and Translational Science, Nedlands, Australia (GRID:grid.482226.8) (ISNI:0000 0004 0437 5686); Murdoch University, Centre for Molecular Medicine and Innovative Therapeutics, Murdoch, Australia (GRID:grid.1025.6) (ISNI:0000 0004 0436 6763) 
16  Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.1025.6); University of Tartu, Estonian Genome Centre, Institute of Genomics, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661) 
17  Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.10939.32); University of Helsinki, Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071) 
18  Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.7737.4); Uppsala University, Department of Medical Sciences, Molecular Precision Medicine and Science for Life Laboratory, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457) 
19  Member of EATRIS ERIC - European Infrastructure for Translational Medicine, Amsterdam, The Netherlands (GRID:grid.8993.b); Uppsala University, Department of Medical Sciences, Molecular Precision Medicine and Science for Life Laboratory, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457) 
20  Weill Cornell Medicine, Department of Physiology and Biophysics, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
21  National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, USA (GRID:grid.419234.9) (ISNI:0000 0004 0604 5429) 
22  National Center for Toxicological Research, U.S. Food and Drug Administration, FDA, Jefferson, USA (GRID:grid.483504.e) (ISNI:0000 0001 2158 7187) 
23  The Center for Drug Evaluation and Research, U.S. Food and Drug Administration, FDA, Silver Spring, USA (GRID:grid.483500.a) (ISNI:0000 0001 2154 2448) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20524463
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2595303947
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.